Crosslink Capital, Inc. (“Crosslink”) was recently informed that someone or an organization has been impersonating it and one or more of its employees on the mobile application WhatsApp.
Crosslink does not market its services and Crosslink and its employees do not provide investment advice through WhatsApp or any similar social media messaging application, and anyone who does so purporting to act in Crosslink’s name or the name of any of its employees is not in any way connected to Crosslink or Crosslink Capital Management, LLC. Crosslink employees provide investment advice only through Crosslink. Crosslink provides investment advice only to investment funds or clients, in each case, with whom it has entered into a written contract. Crosslink does not provide investment or other advice to non-clients.
You can look up investment advisers and their registered persons at: https://adviserinfo.sec.gov/
For more information investing generally, please see: https://www.investor.gov/
September 21, 2021
SAN FRANCISCO, Sept. 21, 2021 /PRNewswire/ — Molekule, the global leader in reinventing air purification, today announced test results in collaboration with the University of Nebraska Medical Center, Department of Pharmacology & Experimental Neuroscience, which demonstrate its PECO air purification technology’s success in removing 99.98% of the COVID-19 virus SARS-CoV-2 from the air, and total destruction rates exceeding 99%. These results are from a multiple pass chamber test and swatch level test, respectively. The multiple pass chamber test utilized an Air Mini device in a small chamber with a single injection of virus aerosol, and the swatch level test used PECO filter media. These results build on other peer-reviewed and published validation of Molekule’s proprietary PECO technology from the University of Minnesota, in which the company demonstrated the inactivation of coronavirus strains (bovine and porcine) and the H1N1 flu virus.
“My team’s testing focused on determining Molekule’s ability to capture and destroy SARS-CoV-2, specifically the strain isolated from Wisconsin,” said Dr. Siddappa Byrareddy, a Professor and Vice-Chair of Research in the Department of Pharmacology & Experimental Neuroscience at the University of Nebraska Medical Center, and the lead researcher on this study. Read rest here.